Department of Neuroscience, Faculty of Medicine, Université de Montréal, and Neuroimmunology Unit, Centre de Recherche du CHUM (CRCHUM), Montréal, QC, Canada.
INRS, Centre Armand-Frappier Santé Biotechnologie, 531, Boulevard des Prairies, Laval, QC, Canada.
Trends Pharmacol Sci. 2020 Jan;41(1):42-54. doi: 10.1016/j.tips.2019.11.001. Epub 2019 Dec 12.
Nanoparticulate carriers, often referred to as nanoparticles (NPs), represent an important pharmacological advance for drug protection and tissue-specific drug delivery. Accessing the central nervous system (CNS), however, is a complex process regulated by mainly three brain barriers. While some leukocyte (i.e., immune cell) subsets are equipped with the adequate molecular machinery to infiltrate the CNS in physiological and/or pathological contexts, the successful delivery of NPs into the CNS remains hindered by the tightness of the brain barriers. Here, we present an overview of the three major brain barriers and the mechanisms allowing leukocytes to migrate across each of them. We subsequently review different immune-inspired and -mediated strategies to deliver NPs into the CNS. Finally, we discuss the prospect of exploiting leukocyte trafficking mechanisms for further progress.
纳米载体,通常被称为纳米颗粒(NPs),是药物保护和组织特异性药物递送的重要药理学进展。然而,进入中枢神经系统(CNS)是一个复杂的过程,主要由三个脑屏障调节。虽然一些白细胞(即免疫细胞)亚群具有在生理和/或病理情况下渗透中枢神经系统的适当分子机制,但 NPs 成功递送到中枢神经系统仍然受到脑屏障紧密性的阻碍。在这里,我们概述了三个主要的脑屏障以及允许白细胞穿过它们的机制。随后,我们回顾了将 NPs 递送到中枢神经系统的不同免疫启发和介导的策略。最后,我们讨论了利用白细胞迁移机制取得进一步进展的前景。